Theravance Biopharma (NASDAQ:TBPH) Posts Earnings Results, Misses Expectations By $0.16 EPS

Theravance Biopharma (NASDAQ:TBPH) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16), Zacks reports. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. The company had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. During the same period in the previous year, the business earned ($0.17) EPS.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH traded up $1.00 during trading on Wednesday, reaching $9.91. The stock had a trading volume of 168,996 shares, compared to its average volume of 345,809. The business has a fifty day moving average price of $8.32 and a 200-day moving average price of $8.68. Theravance Biopharma has a 1-year low of $7.44 and a 1-year high of $11.71. The stock has a market cap of $484.82 million, a PE ratio of -9.92 and a beta of 0.25.

Analyst Ratings Changes

A number of research firms have commented on TBPH. Leerink Partners cut Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research note on Monday, September 16th. TD Cowen cut their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. Finally, Leerink Partnrs lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.